Point-of-care screening test for early cervical cancer detection
用于早期宫颈癌检测的护理点筛查测试
基本信息
- 批准号:10650144
- 负责人:
- 金额:$ 40.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-22 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Acetic AcidsAntibodiesAreaBindingBiological AssayBiological MarkersBiomedical EngineeringBlindedBuffersCDKN2A geneCancerousCaringCause of DeathCell Culture TechniquesCervicalCervical Cancer ScreeningCervical Intraepithelial NeoplasiaCessation of lifeCharacteristicsClinicalCold TherapyCountryCytologyCytolysisDetectionDevelopmentDevicesDiagnosticDiseaseDisease ProgressionDisparityEarly DiagnosisEnsureEnzyme-Linked Immunosorbent AssayEvaluationFlowersGoalsGynecologic OncologistHealth PersonnelHealthcareHorseradish PeroxidaseHuman Papilloma Virus VaccinationHuman PapillomavirusHuman ResourcesHuman papilloma virus infectionImmunoassayIncidenceIncomeInfertilityInfrastructureLaboratoriesLesionMCM2 geneMalignant NeoplasmsMalignant neoplasm of cervix uteriMarketingMethodsMonitorNorth CarolinaOutcomePap smearPaperPathologistPatientsPerformancePoliciesPredictive ValuePremature BirthPreventionPrimary PreventionProcessProteinsRapid screeningRare DiseasesReagentReceiver Operating CharacteristicsRefrigerationResource-limited settingResourcesRisk ReductionRuralSamplingScientistScreening procedureSensitivity and SpecificitySignal TransductionSpecialistSpecificitySpecimenStep TestsSwabTOP2A geneTechniquesTechnologyTestingTimeUnited StatesUniversitiesVaccinesVisitVisualWomanWorld Health OrganizationZambiabeta Actincancer biomarkerscancer health disparitycancer invasivenessclinical infrastructureclinically relevantearly screeningfollow-uphealth care availabilityhealth care deliveryhealth care disparityhigh riskhigh risk populationinfection rateinsightinstrumentationlow and middle-income countriesmortalitymultiplex detectionnanoGoldovertreatmentperformance testspoint of carepoint of care testingpremalignantprogramsprotein biomarkersprotein purificationrisk stratificationrural Americasample collectionscale upscreeningscreening programskillsstandard of caretumor progressiontwo-dimensionalvalosin-containing proteinviral detection
项目摘要
SUMMARY ABSTRACT
Although cervical cancer is an easily curable disease if detected early, it continues to claim the lives of
hundreds of thousands of women worldwide. Healthcare disparities have resulted in cervical cancer incidence
and mortality that are five times higher in low and middle income countries (LMICs) than in high-income countries.
In the United States, cervical cancer mortality rates are twice as high among rural women than their urban
counterparts. The wide disparity in cervical cancer incidence rates and deaths is attributed to both higher HPV
infection rates and a lack of accessible screening and treatment of pre-invasive cervical lesions.
The current standard of care in the US, a cytology-based Pap smear, requires resource intensive laboratory
and clinical specialists with a long turnaround time from sample collection to result. Alternatives, such as visual
inspection with acetic acid and emerging HPV-targeted tests, have poor specificity for cervical cancer, leading
to overtreatment that can cause complications including infertility and pre-term births and that further the burden
on limited healthcare resources. This proposal aims to create an integrated point-of-care screening test that can
be used by healthcare providers in under-resourced settings to obtain relevant clinical insights, including cervical
cancer risk stratification, and enable same-visit treatment of high risk cervical lesions.
Building on our preliminary development of a highly sensitive paper-based immunoassay to test for the key
cervical cancer biomarker, valosin containing protein (VCP), the objective of this proposal is to combine VCP
detection with three other known cervical cancer protein biomarkers, in a sensitive and specific single-step point-
of-care assay.
Specific milestones include:
1) Integrating and optimizing multiplex detection of cervical cancer biomarkers into a simple paper-based
sample-to-answer device.
2) Evaluating the operational and performance metrics of the test in retrospective cervical swab samples.
The outcome of this proposal will be a highly characterized point-of-care test with high sensitivity (95%) and
specificity (90%) to detect high-risk cervical intraepithelial neoplasia and invasive cervical cancer within 40
minutes. This affordable solution for cervical cancer screening and control programs will be applicable in LMICs
and will provide highly sensitive monitoring of cervical intraepithelial neoplasia in the US, where it will be
especially impactful in high-risk populations that are currently underserved by existing screening programs.
摘要摘要
尽管宫颈癌如果及早发现是一种很容易治愈的疾病,但它仍在夺走许多人的生命
全世界有成千上万的女性。医疗保健差距导致了宫颈癌的发病率
低收入和中等收入国家的死亡率是高收入国家的五倍。
在美国,农村妇女的宫颈癌死亡率是城市妇女的两倍
对口单位。宫颈癌发病率和死亡率的巨大差异归因于较高的HPV
感染率和缺乏可获得的宫颈侵袭前病变的筛查和治疗。
美国目前的护理标准是基于细胞学的巴氏涂片,需要资源密集型实验室
和临床专家,从样本收集到结果需要很长的周转时间。可选方案,如视觉
醋酸检查和新兴的HPV靶向检测对宫颈癌的特异性较差,领先
过度治疗可能导致包括不孕不育和早产在内的并发症,并进一步加重负担
有限的医疗资源。该提案旨在创建一种综合的护理点筛查测试,该测试可以
在资源不足的情况下由医疗保健提供者使用,以获得相关的临床见解,包括宫颈
癌症风险分层,并实现高危宫颈病变的同一就诊治疗。
在我们初步开发的高灵敏度纸基免疫分析的基础上,测试关键
宫颈癌生物标记物,含有Valosin的蛋白(VCP),本提案的目的是结合VCP
与其他三个已知的宫颈癌蛋白生物标志物一起检测,在一个敏感和特定的单步点-
Of-Care分析。
具体里程碑包括:
1)将宫颈癌生物标志物的多重检测集成和优化到简单的纸质基础上
样本到答案的设备。
2)在回溯性宫颈拭子样本中评估检测的操作和性能指标。
这项提议的结果将是一项具有高度特征性的、具有高敏感性(95%)和
检测高危宫颈上皮内瘤变和浸润性宫颈癌的特异度(90%)在40
几分钟。这一负担得起的宫颈癌筛查和控制程序解决方案将适用于LMIC
并将在美国提供对宫颈上皮内瘤变的高度敏感的监测,它将在那里
尤其是对目前未得到现有筛查计划服务的高危人群。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacqueline Linnes其他文献
Jacqueline Linnes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacqueline Linnes', 18)}}的其他基金
Point-of-care screening test for early cervical cancer detection
用于早期宫颈癌检测的护理点筛查测试
- 批准号:
10443827 - 财政年份:2020
- 资助金额:
$ 40.54万 - 项目类别:
Point-of-care screening test for early cervical cancer detection
用于早期宫颈癌检测的护理点筛查测试
- 批准号:
10267737 - 财政年份:2020
- 资助金额:
$ 40.54万 - 项目类别:
Pont-of-use Acute HIV Infection Diagnostic for Substance Using Populations
针对药物使用人群的使用点急性 HIV 感染诊断
- 批准号:
10056083 - 财政年份:2020
- 资助金额:
$ 40.54万 - 项目类别:
Pont-of-use Acute HIV Infection Diagnostic for Substance Using Populations
针对药物使用人群的使用点急性 HIV 感染诊断
- 批准号:
10794830 - 财政年份:2020
- 资助金额:
$ 40.54万 - 项目类别:
Smartphone-based diagnostic for HIV self-testing
基于智能手机的 HIV 自检诊断
- 批准号:
10455110 - 财政年份:2018
- 资助金额:
$ 40.54万 - 项目类别:
Smartphone-based diagnostic for HIV self-testing
基于智能手机的 HIV 自检诊断
- 批准号:
10423656 - 财政年份:2018
- 资助金额:
$ 40.54万 - 项目类别:
Smartphone-based diagnostic for HIV self-testing
基于智能手机的 HIV 自检诊断
- 批准号:
9756313 - 财政年份:2018
- 资助金额:
$ 40.54万 - 项目类别:
A Rapid Instrument Free Molecular Diagnostic for B. Pertussis
百日咳博德特氏菌的快速无仪器分子诊断
- 批准号:
8718586 - 财政年份:2014
- 资助金额:
$ 40.54万 - 项目类别:
A Rapid Instrument Free Molecular Diagnostic for B. Pertussis
百日咳博德特氏菌的快速无仪器分子诊断
- 批准号:
8802766 - 财政年份:2014
- 资助金额:
$ 40.54万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 40.54万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 40.54万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 40.54万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 40.54万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 40.54万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 40.54万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 40.54万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 40.54万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 40.54万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 40.54万 - 项目类别:














{{item.name}}会员




